Source: Aimia Inc.
  • Aimia Inc. (AIM) has sold approximately $7.36 million of its common shares to investor company Mithaq Capital SPC
  • Aimia Inc is a holding company that makes long-term investments in public and private companies on a global scale
  • Mithaq Capital is a Saudi family investment office
  • The offering included 1.97 million Aimia common shares for $3.7278 each
  • Mithaq now owns 14.91 per cent of Aimias total common shares
  • Aimia Inc. (AIM) is down 0.27 per cent trading at $3.73 per share as of 3:51 p.m. EST

Aimia (AIM) has sold approximately $7.36 million of its common shares to investor company Mithaq Capital SPC.

Aimia Inc is a holding company that makes long-term investments in public and private companies on a global scale and Mithaq is a Saudi family investment office.

The offering included 1.97 million Aimia common shares with an average price of $3.7278 per common share. As a result, Mithaq has a total ownership of 12.62 million Aimia common shares, which represents approximately 14.91 per cent of the company’s total issued and outstanding common shares.

Just before this acquisition, Mithaq had exercised control or direction over roughly 12.58 per cent of the total common shares.

Mithaq has the opportunity to explore alternatives such as increasing or decreasing its position in Aimia, signing transactions that increase its economic exposure, or continuing to hold its current position. It can also pursue additional plans such as development or taking actions regarding Aimia itself or with joint actors.

Mithaq may also engage with management of Aimia regarding its business, management, operations, capitalization, financial condition, governance, strategy and future plans.

Aimia Inc. (AIM) is down 0.27 per cent trading at $3.73 per share as of 3:51 p.m. EST.


More From The Market Online

@ the Bell: TSX recovers and S&P hits fresh high

Energy shares led enough of a rally to overcome industrials and tech losses to push the TSX to a positive end on Tuesday.

Pathologists group accepts Telo Genomics’ test for rare blood cancer

The College of American Pathologists accepts the Telo Genomics' (TSXV:TELO) submission of a test for a rare blood cancer.

Theralase adds cancer immunotherapy to potential revenue streams

Theralase Technologies' (TSXV:TLT) lead drug candidate, Rutherrin, enhanced cancer immunotherapy in a pre-clinical setting.